Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (2826)	5/18/1999 1:27:00 PM
From: Don Miller	Respond to of 10280

>>SEPR to restore confidence in the Investment Community and eliminate any excessive burning rate<< Nothing the Investment Community or we investors will do can have a serious impact on how successful SEPR drugs can be. The drugs must first be decided improvements, then marketed well. The only questions we have for Nori. is, who will market the advantages and how much will that cost? No matter who markets the drug, the drug's advantage has to carry the marketing cost, some way, some how. Apparently J&J thinks they are weak and inefficient in this marketing field. IMHO, I think we should offer to purchase that force by the way First thing to consider as J&J says they have done, is assess the degree of advantage over what you see the competition will be, and how effective can your marketing team be in overcoming the inferior competition. Bottom Line, if you can overcome the competition, will we make a profit. If we have a superior product, we can make a profit, and we are not hurting another of our drug's profit, then afford the market force that can sell it. Why would we not put more money in, to make even more money??? We have multiple drugs in the same general field coming down the pipe. Remember this same allergy/asthma marketing force could either later sell our other drugs or serve as a bargaining chip in partnering negotiations. We have almost all the antihistamine field covered, let's be patient and not urge them to make an quick but bad partnership.